In September 2019, the 26th annual meeting of the International Society Mechanical Circulatory Support (ISMCS) was held in Japan. The conference brought together well-known doctors, scholars, and researchers in MCS industry. CH Biomedical was invited to participate in this conference for the first time, indicating that the company has become one of the most recognized VAD enterprises today. Dr. Chen Chen, CEO of the company, and Dr. Lin Feng, CTO, attended the meeting and delivered a keynote speech in Device Update session.
At the conference, Dr. Chen shared the latest In-Vitro and In-Vivo test results of the new fully maglev CH-VAD®. Dr. Chen introduced that CH Biomedical had developed a new generation of all-magnetic levitation ventricular assist device (CH-VAD®) through multi-disciplinary and multi-level of R&D and design based on brand-new patent. In pump flow path design, the Computational Fluid Dynamics (CFD) technology was used to optimize the flow channel structure, thus allowing smooth turning of blood flow, which greatly reduced the shear stress on the blood during the pumping process. The reliability of the system is also improved by using the new miniaturization electronic technology that integrates the control electronic components into the pump. The good hemocompatibility of the product was further verified by in-vitro hemolysis test and animal studies. All these achievements had drawn high attention of the participants, and CH-VAD® had been highly recognized by the MCS industry.
The mission of ISMCS (formerly known as International Society for Rotary Blood Pumps ISRBP) is "Save lives and improve the quality of life". The ultimate goal of ISMCS is to provide cross-disciplinary scientific and clinical technical support, and bring new cost-efficient solutions to MCS industry. The Society provides an international platform for in-depth discussion on the theory, research and clinical application of mechanical circulatory support through its annual meeting. CH Biomedical was honored to participate in this conference and deliver a report. In the future, the company looks forward to communicating and cooperating with more colleagues in the industry, so that more patients with advanced heart failure can enjoy a healthy and beautiful life again with the help of ventricular assist devices.
May 24-27, 2022 International Society for Mechanical Circulatory Society (ISMCS) and European Mechanical Circulatory Society (EUMS) Joint Scientific Conference was successfully held in Hanover, Germany. Dr. Frank Lin, PhD, CTO of CH Biomedical, and Mr. Karl Nelson, Vice President of Clinical Operations were invited to attend the conference.
On November 25th 2021, the implantable CH-VAD® left ventricular assist system (CH-VAD® LVAS) of CH Biomedical was approved by the National Medical Products Administration (NMPA) for marketing (Registration No.: GXZZ 20213120987). CH-VAD LVAS was developed independently by CH Biomedical, it is the first Left Ventricular Assist Device (LVAD) with complete independent intellectual property rights approved by NMPA in China, and the first full magnetic levitation LVAD approved by NMPA.
From 9th to 14th of June 2019, the Gordon Research Conference was held in Barcelona, Spain. The conference theme this year was on Mechanical Circulatory Support (MCS) and brought together world-renowned doctors, scholars, and researchers in MCS field. Dr. Chen, CEO of the company, and Dr. Lin, CTO were invited to attend the conference and delivered a plenary speech.